Resonance Health Ltd · ASX:RHT
Resonance Health — Investor Presentation (February 2005)
22 slides from Resonance Health's investor presentation, February 2005
Slide 1: Commercialising the FerriScan Technology: The Future of Liver Diagnosis
Commercialising the FerriScan™ Technology “The Future of Liver Diagnosis” Investor Update February 2005 1
Slide 2: Commercialising the FerriScan Technology
Commercialising the FerriScan™ Technology “The Future of Liver Diagnosis” • Resonance Health (ASX:RHT) – specialises in liver diagnostic imaging technology. • The FerriScan™ Technology is a novel, non-invasive liver diagnostic with global applications developed by a multi-disciplinary team at The Un
Slide 3: What is the FerriScan Technology
What is the FerriScan™ Technology • A safe, non-invasive and accurate test to measure liver iron concentration • Utilises existing MRI equipment, proprietary software and a patented iron “marker” known as “R2”. • Provides clinicians around the world with a new and safe diagnostic tool to track liver
Slide 4: Why Test for Iron Overload?
Why Test for Iron Overload? • Chronic disorders of iron metabolism are among the most common diseases (1 in 200 for HHC). • The result is too much iron is absorbed by the digestive system and accumulates in the body (and in its largest organ – the liver). • Iron overload has previously been difficul
Slide 5: Diseases Associated With Iron Overload
Diseases Associated With Iron Overload • Thalassaemia (minor & major) – Hereditary conditions prevalent in people of Mediterranean descent and in parts of South East Asia. Thalassaemia (major) is a very severe and debilitating form of anemia (typically a terminal illness). • Haemochromatosis – A her
Slide 6: Liver Biopsy is the Current Gold Standard for Measuring Liver Iron
Liver Biopsy is the Current “Gold Standard” for Measuring Liver Iron If an effective alternative were available, would patients choose needle biopsy? 6
Slide 7: The FerriScan Test Process Leverages Existing MRI Infrastructure
The FerriScan™ Test Process Leverages Existing MRI Infrastructure •Utilizes existing MRI scanners with no new equipment purchases •MRI Images processed off-line at a central centre, using IVB proprietary software, optimising quality control and security of the technology •Provides a clear, unambiguo
Slide 8: Available Globally – Processed Locally
Available Globally – Processed Locally • MRI units can be enabled remotely to incorporate the IVB Technology and to perform the FerriScan™ Test (currently 45 units enabled in USA, South America, Europe, The Middle East, Asia & Australia) • Liver Scans from the MRI (off-line) are sent via the Interne
Slide 9: FerriScan offers significant benefits over the gold standard alternative
FerriScan™ offers significant benefits over the “gold standard” alternative for iron level tests FerriScan™ Liver Needle Biopsy 1. Non-invasive and painless 1. Invasive, painful and a potential 2. Can be performed regularly if health risk from bleeding necessary 2. Can only be performed about 3. No
Slide 10: Market Potential: FerriScan / Iron Overload Application
Market Potential: FerriScan ™ / Iron Overload Application • Iron loading disorders prevalence approximately 1% of developed world population. • Australia: – 125,000 potential patients • U.K: – 500,000 potential patients • U.S. > 2 million potential patients • World market potential value for FerriSc
Slide 11: Other Direct Applications for the FerriScan Technology Platform
Other Direct Applications for the FerriScan™ Technology Platform • Hepatitis C – Assessment of liver iron levels to ensure the efficacy of prescribed drug treatments (1 in 100 people in developed countries). • Adjunct to blood tests in the diagnosis of Hereditary Haemochromatosis (HHC) or to rule ou
Slide 12: FerriScan Has The Potential To Reduce Cost & Increase Patient Acceptability
FerriScan™ Has The Potential To Reduce Cost & Increase Patient Acceptability Providers / Reduced cost of care Reimbursement Groups Increased patient monitoring and safety Only a liver biopsy provides information on possible A Liver Biopsy is the contributions of iron to the progression of iron overl
Slide 13: Distribution Map – Iron Overload Disorders
Distribution Map – Iron Overload Disorders 4,000,000 10,000,000 100,000 13
Slide 14: USA & Australian Market Potential
FerriScan™ / Iron Overload Application USA & Australian Market Potential Total Australia USA Population (USA & AUST) 289,000,000 20,000,000 270,000,000 Prevalence population, iron 2,125,000 125,000 2,000,000 overload. Potential FerriScan™ test 4,250,000 250,000 4,000,000 volume (@ 2 tests / pt / yr)
Slide 15: Growth in Current Diagnostic Tests for Iron Overload
Growth in Current Diagnostic Tests for Iron Overload Blood iron studies growth in Australia (serum iron & transferrin or iron binding c apac ity & ferritin) 2,000,000 1,401,005 1,500,000 1,041,971 1,250,347 Over a five year consecutive 877,048 1,000,000 731,138 period (1999-2003) financial 500,000 y
Slide 16: Potential FerriScan Test Pricing
Potential FerriScan™ Test Pricing FerriScan™ Test* Biopsy Australia: FerriScan™ Test (revenue) $300 MRI Scan $300 Patient Cost (before reimbursement) $600 $1,450 USA: (in AUD$) FerriScan™ Test (revenue) $450 MRI Scan $600 Patient Cost (before reimbursement) $1,050 $1,750-$2,000 * Note: Pricing is in
Slide 17: FerriScan Indicative Model of Potential Gross Profit
FerriScan™ Indicative Model of Potential Gross Profit Based on Potential Potential Test Numbers Revenue 1 Est. %GM Gross Profit 50,000 $15M 50% $7.5M 100,000 $30M 55% $16.5M 150,000 $45M 60% $27M 200,000 2 $60M 65% $39M Note: 1 At revenue of AUD$300 per test 2 200,000 tests represents 5% of the pote
Slide 18: Board of Directors – Resonance Health
Board of Directors – Resonance Health • Hon. Dr Michael Wooldridge (Non-Executive Chairman) – Former Federal Minister for Health • Mr Tony Fitzgerald (Executive Director) – Legal and healthcare licensing expertise, 18 years experience in commercialising healthcare and biotech projects • Dr Christine
Slide 19: Capital Structure
Capital Structure (As at 1 February 2005) Shares – Listed Listed Shares on issue (RHT) 111,353,585 Market Capitalisation (@ 31 Jan 05 RHT Share price of $0.24) $26.7 M Options – Listed (exercise prices): RHTOA Options ($0.15 to 15 Jan 2007) 44,461,309 RHTOB Options ($0.40 to 15 Jan 2008) 20,605,194
Slide 20: Benchmark examples of Diagnostic Imaging companies
Benchmark examples of Diagnostic Imaging companies Medical Device Medical IT Solution Diagnostic Service Company Description Mkt Cap: Cash: Status MedicSight Medicsight is a medical imaging software company. Its MC: US$165m FDA approvals for three products (USA) core technology is focused on develop
Slide 21: Major Progress Towards Commercialisation of FerriScan
Major Progress Towards Commercialisation of FerriScan™ 1. TGA listing achieved in Australia – December 2004 2. European marketing approval – CE Mark achieved, January 2005 3. US FDA 510(k) clearance received January 2005 4. Major radiology partner identified for initial Australian commercial roll-ou
Slide 22: Forward looking statements and risks
Forward looking statements and risks This presentation contains forward-looking statements that are based on management’s current expectations. These statements may differ materially from actual future events or results due to the range of risks and uncertainties associated with the healthcare techn
Resonance Health — Investor Presentation (February 2005) on 6ix